WEBINAR

January 1, 2018

Interrogating Cancer Drivers via CRISPR: Mutant TP53 as a Therapeutic Target in Hypodiploid B-cell Acute Lymphoblastic Leukemia

You May Also Like…

CONTENT

Research Snapshot: Enrichment of Viable Human PBMCs with Levitation Technology

EVENT

Flow Cytometry UK | July 20-22 | Birmingham, UK